Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.52
(
0.36%
)
Bitcoin
68,723.01
(
1.30%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 160455

Monday, 04/29/2013 1:43:29 PM

Monday, April 29, 2013 1:43:29 PM

Post# of 257269

GILD—Could failure to achieve GT3 labeling for Sofo/Riba, within the pooled data filing, delay approval for GT2 patients? Is it possible GILD would be required to refile the Sofo/Riba NDA for GT2?

I don’t think so. The data appear solid enough in GT2 to warrant approval on the current review cycle.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today